Online inquiry

IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ8326MR)

This product GTTS-WQ8326MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets TFRC gene. The antibody can be applied in Glioblastoma research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Corynebacterium diphtheriae; Homo sapiens
RefSeq	NM_001128148.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	7037
UniProt ID	P02786

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8326MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ3013MR	IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	Anti-Beta7
GTTS-WQ13789MR	IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	REGN-10933
GTTS-WQ6894MR	IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	E-6011
GTTS-WQ13755MR	IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	REGN 1500
GTTS-WQ4686MR	IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	BMS-986089
GTTS-WQ12051MR	IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	MNRP1685A
GTTS-WQ5633MR	IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	CDP870
GTTS-WQ15067MR	IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	SSS-23

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST